---
schema_version: "secwatch.filing_event.v1"
accession: "0001479290-24-000034"
form_type: "8-K"
ticker: null
cik: "0001479290"
company_name: "Revance Therapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:37:49.177102+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Revance Q4 product revenue $58.5M (+28%); guides 2024 at least $280M

## Summary
- Q4 product revenue $58.5M (DAXXIFY $24M, RHA $34.5M); full year product $212.7M (+80% YoY).
- 2024 product revenue guidance at least $280M; DAXXIFY cervical dystonia launch mid-year.
- GAAP net loss FY 2023 $324M; Adjusted EBITDA loss $160.1M; cash $253.9M as of Dec 31.
- President Dustin Sjuts steps down effective March 31; separation includes 18 months base salary.
- OPUL payments business exit by Q1 2024, generating ~$20M annual savings.

## SEC filing metadata
- accession: 0001479290-24-000034
- form_type: 8-K
- cik: 0001479290
- company_name: Revance Therapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/rvnc-20240223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001479290-24-000034
- JSON: https://secwatch.observer/filing/0001479290-24-000034.json
- Plain text: https://secwatch.observer/filing/0001479290-24-000034.txt

## Key facts
- Earnings Releases
  Revance Therapeutics, Inc. updated its 2024 guidance (initiated).
  - Period: 2024
  - Guidance: initiated
  - Result: guidance update
  source text: 2024 product revenue guidance of at least $280 million, supporting blockbuster potential in U.S. aesthetics.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm
- Earnings Releases
  Revance Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2023 guidance (initiated).
  - Period: the fourth quarter and full year ended December 31, 2023
  - Guidance: initiated
  - Result: reported results
  source text: On February 28, 2024, the Company issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and the Company's financial outlook for 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm
- Executive change
  Dustin Sjuts departed as President at Revance Therapeutics, Inc..
  - Action: stepping down
  - Role: President
  source text: On January 8, 2024, the Company announced that Mr. Sjuts is stepping down from his current position as President of the Company, effective as of March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm
- Material Agreements
  Revance Therapeutics, Inc. amended Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services (effective 2024-02-26).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services
  - Effective: 2024-02-26
  source text: On February 26, 2024, Revance Therapeutics, Inc. (the “Company”) and Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services, a contract development and manufacturing organization (“ABPS”), entered into Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Amendment”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.